Free Trial
NASDAQ:VAXX

Vaxxinity (VAXX) Stock Price, News & Analysis

Vaxxinity logo
$0.0010
0.00 (0.00%)
(As of 11/4/2024 ET)

About Vaxxinity Stock (NASDAQ:VAXX)

Key Stats

Today's Range
$0.0010
$0.0010
50-Day Range
$0.00
$0.10
52-Week Range
$0.00
$1.33
Volume
17,568 shs
Average Volume
800,622 shs
Market Capitalization
$126,748.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

VAXX Stock News Headlines

Brain health
Treatment Trials in Alzheimer's Disease
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
Vaxxinity Plans to Delist Shares From Nasdaq
Vaxxinity Issues Shareholder Letter
See More Headlines

VAXX Stock Analysis - Frequently Asked Questions

Vaxxinity's stock was trading at $0.85 at the beginning of 2024. Since then, VAXX shares have decreased by 99.9% and is now trading at $0.0010.
View the best growth stocks for 2024 here
.

Vaxxinity, Inc. (NASDAQ:VAXX) posted its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16).

Vaxxinity (VAXX) raised $90 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxxinity investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Rivian Automotive (RIVN) and Tesla (TSLA).

Company Calendar

Last Earnings
3/27/2023
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VAXX
Fax
N/A
Employees
90
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$0.11 per share

Miscellaneous

Free Float
45,553,000
Market Cap
$126,748.00
Optionable
Not Optionable
Beta
0.94
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VAXX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners